LMR Partners’s Seres Therapeutics MCRB Stock Holding History

LMR Partners’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,255	Closed	-$1.01M	–	1228
2021 Q3	$1.01M	Buy	+7,255	New	+$1.42M	0.01%	617

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LMR Partners's MCRB Position: Q4 2021 in Review

LMR Partners sold out of Seres Therapeutics (MCRB) in Q4 2021, closing a stake of 7,255 shares — an estimated $1.01M sold.

LMR Partners first reported a position in MCRB in Q3 2021 and held it in 1 quarter. The position peaked at $1.01M in Q3 2021. 148 funds tracked by Wall St. Rank hold MCRB as of Q4 2021.

LMR Partners reported no remaining Seres Therapeutics position as of Q4 2021 after selling out during the quarter.
LMR Partners sold 7,255 Seres Therapeutics shares in Q4 2021, an estimated $1.01M.
LMR Partners first reported a position in Seres Therapeutics in Q3 2021 and held it in 1 quarter.
LMR Partners's Seres Therapeutics position peaked at $1.01M in Q3 2021.
148 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2021.

Based on LMR Partners's 13F filing for Q4 2021, filed 14 Feb 2022.